Published in Am J Obstet Gynecol on October 01, 1990
Intrauterine diagnosis of cytomegalovirus and rubella infections by amniocentesis. CMAJ (1991) 1.43
Prenatal diagnosis of congenital cytomegalovirus infection. J Clin Microbiol (1998) 1.10
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Partner's influence on patient preference for treatment in early prostate cancer. BJU Int (2003) 2.33
Role of cytoplasmic vacuoles in varicella-zoster virus glycoprotein trafficking and virion envelopment. J Virol (1988) 2.22
Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect Immun (1978) 2.15
Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J Virol (1997) 2.14
Structural analysis of the varicella-zoster virus gp98-gp62 complex: posttranslational addition of N-linked and O-linked oligosaccharide moieties. J Virol (1985) 2.09
Primary Epstein-Barr-virus infections in acute neurologic diseases. N Engl J Med (1975) 2.02
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
Phosphorylation of varicella-zoster virus open reading frame (ORF) 62 regulatory product by viral ORF 47-associated protein kinase. J Virol (1994) 1.99
Monoclonal antibodies against three major glycoproteins of varicella-zoster virus. Infect Immun (1983) 1.95
Egress of varicella-zoster virus from the melanoma cell: a tropism for the melanocyte. J Virol (1995) 1.89
Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol (1992) 1.81
The synthesis of glycoproteins in human melanoma cells infected with varicella-zoster virus. Virology (1980) 1.72
Cell surface expression and fusion by the varicella-zoster virus gH:gL glycoprotein complex: analysis by laser scanning confocal microscopy. Virology (1995) 1.72
Variation on a theme by Fenner: the pathogenesis of chickenpox. Pediatrics (1981) 1.69
Cell-free varicella-zoster virus in cultured human melanoma cells. J Gen Virol (1979) 1.64
Complex formation facilitates endocytosis of the varicella-zoster virus gE:gI Fc receptor. J Virol (1998) 1.62
New common nomenclature for glycoprotein genes of varicella-zoster virus and their glycosylated products. J Virol (1986) 1.59
Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. J Virol (1993) 1.58
Consensus: varicella-zoster infections in pregnancy and the perinatal period. Pediatr Infect Dis J (1990) 1.53
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Identification and mapping of single nucleotide polymorphisms in the varicella-zoster virus genome. Virology (2001) 1.50
Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol (1997) 1.50
Site-directed mutagenesis of herpesvirus glycoprotein phosphorylation sites by recombination polymerase chain reaction. PCR Methods Appl (1992) 1.49
Varicella-zoster virus-specific gp140: a highly immunogenic and disulfide-linked structural glycoprotein. Virology (1984) 1.49
Multiple regulatory effects of varicella-zoster virus (VZV) gL on trafficking patterns and fusogenic properties of VZV gH. J Virol (1996) 1.49
Serine protein kinase associated with varicella-zoster virus ORF 47. Virology (1992) 1.48
Neutralization epitope of the varicella-zoster virus gH:gL glycoprotein complex. Virology (1994) 1.46
Pyomyositis in an adolescent female athlete. J Pediatr Surg (1995) 1.43
Complement-enhanced neutralizing antibody response to varicella-zoster virus. J Infect Dis (1979) 1.40
Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J Virol (1993) 1.40
Genomic cartography of varicella-zoster virus: a complete genome-based analysis of strain variability with implications for attenuation and phenotypic differences. Virology (2006) 1.39
Common expression of varicella-zoster viral glycoprotein antigens in vitro and in chickenpox and zoster vesicles. J Infect Dis (1983) 1.39
Varicella-zoster virus ORF47 protein serine kinase: characterization of a cloned, biologically active phosphotransferase and two viral substrates, ORF62 and ORF63. J Virol (2001) 1.37
Entry and egress of varicella virus blocked by same anti-gH monoclonal antibody. Virology (1993) 1.36
Antigenic variation of varicella zoster virus Fc receptor gE: loss of a major B cell epitope in the ectodomain. Virology (1998) 1.35
Varicella-zoster Virus gB and gE coexpression, but not gB or gE alone, leads to abundant fusion and syncytium formation equivalent to those from gH and gL coexpression. J Virol (2001) 1.29
Cell surface expression of the varicella-zoster virus glycoproteins and Fc receptor. Virology (1990) 1.29
Interactions among structural proteins of varicella zoster virus. Arch Virol Suppl (2001) 1.27
Neutralization epitope of varicella zoster virus on native viral glycoprotein gp118 (VZV glycoprotein gpIII). Virology (1986) 1.23
Chaperone functions common to nonhomologous Epstein-Barr virus gL and Varicella-Zoster virus gL proteins. J Virol (1997) 1.18
Varicella zoster virus glycoprotein gpI is selectively phosphorylated by a virus-induced protein kinase. Proc Natl Acad Sci U S A (1986) 1.18
Bell's palsy and infectious mononucleosis. Lancet (1973) 1.17
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Varicella-zoster virus Fc receptor component gI is phosphorylated on its endodomain by a cyclin-dependent kinase. J Virol (1999) 1.13
Molecular dissection of the humoral immune response to individual varicella-zoster viral proteins during chickenpox, quiescence, reinfection, and reactivation. J Infect Dis (1984) 1.13
Unusual phosphorylation sequence in the gpIV (gI) component of the varicella-zoster virus gpI-gpIV glycoprotein complex (VZV gE-gI complex). J Virol (1994) 1.13
Assembly and processing of the disulfide-linked varicella-zoster virus glycoprotein gpII(140). J Virol (1987) 1.07
Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins. J Virol (1985) 1.03
Epstein-Barr virus and Guillain-Barré syndrome. Lancet (1972) 1.03
Herpesvirus antibody levels in the etiologic diagnosis of the acute retinal necrosis syndrome. Am J Ophthalmol (1992) 1.02
Cryopreservation of varicella-zoster virions without loss of structural integrity or infectivity. Intervirology (1981) 1.02
Immunoprecipitable polypeptides specified by varicella-zoster virus. Virology (1982) 1.01
Varicella-zoster virus p32/p36 complex is present in both the viral capsid and the nuclear matrix of the infected cell. J Virol (1986) 1.00
Immunogenic glycoproteins of laboratory and vaccine strains of Varicella-Zoster virus. Infect Immun (1981) 0.99
Cellular and humoral immunity to varicella zoster virus glycoproteins in immune and susceptible human subjects. J Infect Dis (1989) 0.98
Purification and molecular anatomy of the varicella-zoster virion. Biken J (1983) 0.96
Epitope mapping and tagging by recombination PCR mutagenesis. Biotechniques (1997) 0.95
Varicella-zoster viral glycoprotein envelopment: ultrastructural cytochemical localization. J Histochem Cytochem (1986) 0.95
Zoster in children with cancer: radioimmune precipitation profiles of sera before and after illness. J Infect Dis (1983) 0.95
Varicella-zoster virus glycoprotein gE: endocytosis and trafficking of the Fc receptor. J Infect Dis (1998) 0.93
Mechanism of selective nonspecific cell-mediated cytotoxicity of virus-infected cells. Nature (1976) 0.92
Primary Epstein-Barr virus infection in a renal transplant recipient. South Med J (1977) 0.92
Glycoprotein gp118 of varicella-zoster virus: purification by serial affinity chromatography. J Virol (1984) 0.91
Immunization of inbred guinea pigs with varicella-zoster virus grown in a syngeneic transformed embryo cell line. J Clin Microbiol (1981) 0.90
DNA mapping of paired varicella-zoster virus isolates from patients with shingles. Lancet (1983) 0.89
Genomic analysis of varicella-zoster virus: primers for individual open reading frames. J Clin Virol (2003) 0.88
Transformation of primary chick embryo fibroblasts by Marek's disease virus. Virology (1997) 0.88
Normal values for human umbilical venous and amniotic fluid pressures and their alteration by fetal disease. Am J Obstet Gynecol (1989) 0.87
Cerebroside antibody titers in antisera capable of myelination inhibition and demyelination. Brain Res (1978) 0.86
Pyomyositis presenting as acute abdominal pain. Pediatr Infect Dis (1984) 0.85
Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not. J Gen Virol (2001) 0.85
Magnetic resonance imaging of the brain in childhood herpesvirus infections. Pediatr Infect Dis J (1987) 0.85
Cellular immunodeficiency associated with nucleoside phosphorylase deficiency. Immunologic and biochemical studies. Clin Immunol Immunopathol (1977) 0.84
Epstein-Barr virus and transverse myelitis. Lancet (1973) 0.82
Evaluation of severe growth retardation using cordocentesis--hematologic and metabolic alterations by etiology. Obstet Gynecol (1989) 0.82
Varicella pneumonitis: immunodiagnosis with a monoclonal antibody. J Pediatr (1984) 0.81
Insulin-degrading enzyme binds to the nonglycosylated precursor of varicella-zoster virus gE protein found in the endoplasmic reticulum. J Virol (2009) 0.81
Effect of varying degrees of "normal" glucose metabolism on maternal and perinatal outcome. Am J Obstet Gynecol (1988) 0.80
Herpesviral Fc receptors and their relationship to the human Fc receptors. Immunol Res (1992) 0.80
Subacute sclerosing panencephalitis, a measles complication, in an internationally adopted child. Emerg Infect Dis (2000) 0.80
The effect of fetal age upon normal fetal laboratory values and venous pressure. Obstet Gynecol (1992) 0.79
Letter: Measles associated with Bell palsy. Am J Dis Child (1975) 0.79
Staphylococcal pyomyositis in South Texas. J Pediatr (1978) 0.79
Bad consequences of bicycle accidents. Pyomyositis. Pediatr Infect Dis J (1994) 0.79
Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis J (1988) 0.78
Biotinylated and radioactive DNA probes for detection of varicella-zoster virus genome in infected human cells. Mol Cell Probes (1988) 0.78
IgM and IgG responses to varicella-zoster virus p32/p36 complex after chickenpox and zoster, congenital and subclinical infections, and vaccination. J Infect Dis (1989) 0.78
Magnetic resonance imaging for early diagnosis of necrotizing fasciitis. Pediatr Emerg Care (1993) 0.78
Diagnosis, pathophysiology, and treatment of chronic twin-to-twin transfusion syndrome. Fetal Diagn Ther (1995) 0.78
Complete spectrum of the varicella congenital defects syndrome in 5-year-old child. Pediatr Infect Dis (1984) 0.78
Guillain-Barré syndrome following administration of live measles vaccine. Am J Med (1976) 0.78
Fatal pertussis in an Iowa infant. Iowa Med (1991) 0.78
Varicella-zoster virus with a lost gE epitope: evidence for immunological pressure by the human antibody response. Arch Virol Suppl (2001) 0.77
Prenatal diagnosis of second-trimester congenital varicella syndrome by virus-specific immunoglobulin M. J Pediatr (1987) 0.77
The cell surface in amoeboid locomotion--studies on the role of cell-substrate adhesion. Cell Biol Int Rep (1982) 0.76
Cordocentesis. Obstet Gynecol Clin North Am (1988) 0.76
Epstein-Barr virus: the hematologic and oncologic consequences of virus-host interaction. Crit Rev Oncol Hematol (1989) 0.76
Pyomyositis in children in the United States. Rev Infect Dis (1991) 0.75
Ceftriaxone vs cefotaxime for treatment of Haemophilus influenzae meningitis. Pediatrics (1990) 0.75